Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
, Baeten D
, Baker T
, Griffiths M
, Ionescu L
, Lawson ADG
, Maroof A
, Oliver R
, Popa S
, Strimenopoulou F
, Vajjah P
, Watling MIL
, Yeremenko N
, Miossec P
, Shaw S
Full Text Sources
Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone.
PMID: 29275332 [PubMed - as supplied by publisher]
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
- [Review] IL-17A: A Unique Pathway in Immune-Mediated Diseases: Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis.
- Heterogeneous expression pattern of interleukin-17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for non-response to anti-IL-17 therapy?
- Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
- First-in-human randomised study of bimekizumab, a humanised monoclonal antibody and selective dual inhibitor of IL-17A and IL-17 F, in mild psoriasis.